Immunovant, Inc.
IMVT
Positions held
Your positionsIMVT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Immunovant, Inc. operates in the biotechnology sector, which is characterized by high growth potential and innovation, particularly in the treatment of autoimmune diseases.
- The company's market cap stands at approximately $6.63 billion, indicating significant investor interest.
- Analysts have a 'buy' recommendation for the stock, with a target mean price of $48.875.
- Immunovant has not generated any revenue in recent quarters, which raises concerns about its sustainability and growth prospects.
- The company reported a net income loss of -153.224 million in Q2 2026, continuing a trend of negative earnings over multiple quarters.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating bearish market sentiment and technical indicators pointing to further declines.
Fundamentals
| Market cap | $6.25B | Enterprise value | $5.45B | Trailing P/E | — | Forward P/E | -11.00 |
| PEG | — | Price / book | 8.49 | Beta | 0.84 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -80.1% | ROA | -46.7% | Debt / equity | — |
| Current ratio | 7.27 | Free cash flow | -$238.70M | Analyst recommendation | none | Mean target | $48.88 |
| 52w high | $45.42 | 52w low | $16.08 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$153M | -$148M | -$111M | -$127M | -$121M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$160M | -$160M | -$114M | -$132M | -$127M | — |
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$506M | -$414M | -$259M | -$211M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$533M | -$438M | -$270M | -$208M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
2026-09-30 · Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
2026-09-29 · Immunovant (IMVT) Just Gave Investors Something To Think About
2026-09-28 · Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
2026-09-27 · Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
2026-09-24 · IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
2026-09-24 · Lilly’s latest China drug deal; Immunovant’s setback in lupus
2026-09-24 · Roivant reports top-line data from IMVT-1402 CLE trial
2026-09-23 · Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
2026-09-23 · Sector Update: Healthcare Stocks Retreat in Afternoon Trading
2026-09-23 · Sector Update: Healthcare Stocks Mixed Premarket Wednesday
2026-09-23 · Sector Update: Healthcare
Price (daily)
Full chart · RSI · MACD · patterns